Crucell to Concentrate Research and Development in Leiden, The Netherlands

01-Nov-2006

Crucell N.V. announced that it will concentrate its research and development (R&D) activities at its Leiden headquarters in The Netherlands. Vaccine manufacturing, regulatory activities, clinical development and vaccine marketing will be concentrated in Crucell's Swiss operations in Bern.

According to Crucell, the decision to concentrate R&D in Leiden has been made to increase efficiency in R&D spending and will result in a reduction in the number of staff employed. Due to the suspension in July 2006 of Aerugen®, the vaccine candidate for the prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients, there are fewer projects requiring development support at Bern. This restructuring shall result in the reduction of approximately 60 positions, mainly in Bern.

Other news from the department business & finance

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics